Last reviewed · How we verify

AZD2115 Dose 1 — Competitive Intelligence Brief

AZD2115 Dose 1 (AZD2115 Dose 1) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

phase 2 Small molecule Live · refreshed every 30 min

Target snapshot

AZD2115 Dose 1 (AZD2115 Dose 1) — Pearl Therapeutics, Inc.. AZD2115 is an investigational drug with an undisclosed mechanism of action.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AZD2115 Dose 1 TARGET AZD2115 Dose 1 Pearl Therapeutics, Inc. phase 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZD2115 Dose 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/azd2115-dose-1. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: